Ventrus Reports Third Quarter 2011 Financial Results
14 nov. 2011 08h05 HE
|
Assembly Biosciences, Inc.
NEW YORK, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2011.
In July, Ventrus received net...
Ventrus Validates Large Patient Potential for VEN 309 With Survey Data From 10,000 Consumers
14 nov. 2011 07h11 HE
|
Assembly Biosciences, Inc.
NEW YORK, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today an update to the timing for the reporting of the top line results from the ongoing Phase 3 pivotal...
Ventrus BioSciences to Announce 3Q 2011 Financial Results, Clinical Update and Omnibus Market Research Results: Conference Call and Webcast
09 nov. 2011 08h00 HE
|
Assembly Biosciences, Inc.
NEW YORK, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research...
Ventrus Announces the Launch of the First Pivotal Trial of VEN 309 for the Treatment of Hemorrhoids
16 août 2011 08h00 HE
|
Assembly Biosciences, Inc.
NEW YORK, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that enrollment has opened at 65 of the 70 sites that will participate in the first pivotal Phase...